9 AUGUST, 2018 – (BEIJING) In another positive development in China’s rapidly evolving regulatory environment The China National Drug Administration (CNDA) has introduced a 60-day window […]
了解更多
Significant changes are ahead for clinical research in China. The Public Consultation Notice for Policies to Encourage Innovation and Reform in Regulation of Drug and Medical Device Clinical T […]
了解更多
Thrombolysis will continue to be the mainstay for acute stroke treatment, despite the recent revolution in neurointerventional clot retrieval. However, as there are ongoing limitations of thrombolysis of bleeding risk and reduced efficacy in large clots – what possible therapeutic advancements can complement or act as an adjuvant to thrombolysis? Neurointervention – effective, but limited […]
了解更多
An at-a-glance round-up of the arrangements for clinical trial applications in 10 countries in the region. Australia Australia is unique in that its Human Research Ethics Committees (HRECs) have responsibility for the oversight and ongoing monitoring of trials, including reviews and approvals. The first step is submission of the clinical trial to the HREC for […]
了解更多
China is Australia’s largest trading partner – worth $8.8 billion in 2014-2015. China and Australia are also growing partners in science and research and this is an important area for growth in bilateral relations. China is and has been Australia’s key focus for science and research collaboration efforts; generating advances in medical research, biodiversity, net […]
了解更多
China’s meteoric growth over the past twenty years (or so) has seen it go from strength to strength, particularly in the clinical trials sector. As the clinical trial market of the world’s mos […]
了解更多
Generally, the unit of randomization in a randomized clinical trial (RCT) is the individual participant (the patient). Occasionally, the unit of randomization can be a cluster, such as hospitals, schools, villages, etc. When randomizing large groups, the concept of cluster randomized trials (CRTs) has become increasingly common. Patient clusters are allocated to the intervention arms […]
了解更多
Active international collaboration has facilitated the rise of the Asia-Pacific region in global clinical research. In the first two parts of this blog series, we’ve discussed how Japan and So […]
了解更多
Japan has taken significant steps in establishing itself as a major player in the global clinical research community, driving the demand for more clinical trials across East Asia as a result. […]
了解更多
On the heels of our recent post on our presence at this week’s DIA Japan 2015, BBK welcomes Philip Gregory, the General Manager of 乔治临床( George Clinical ) – CRO China as our guest contri […]
了解更多
